Zheqing Shen - Nu Skin Independent Director
| NUS Stock | USD 8.12 0.04 0.49% |
Director
Mr. Zheqing Shen is an Independent Director of Nu Skin Enterprises, Inc. Mr. Shen is the founding member of ZQ Capital Limited, a boutique investment and advisory firm. Prior to founding ZQ Capital in 2015, Mr. Shen was managing director and head of the China Financial Institutions Business at Barclays from 2011 to 2015. From 2004 to 2010, he worked with Goldman Sachs as an investment banker in its New York and Hong Kong offices. In addition to his service on our Board, Mr. Shen has also served since 2016 on the board of directors and the Audit, Remuneration and Nomination Committees of KFM Kingdom Holdings Limited, a precision metals engineering and manufacturing company that is listed on the Hong Kong Stock Exchange since 2016.
| Age | 40 |
| Tenure | 9 years |
| Address | 75 West Center Street, Provo, UT, United States, 84601 |
| Phone | 801 345 1000 |
| Web | https://www.nuskin.com |
Nu Skin Management Efficiency
The company has Return on Asset of 0.0342 % which means that on every $100 spent on assets, it made $0.0342 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.199) %, meaning that it generated no profit with money invested by stockholders. Nu Skin's management efficiency ratios could be used to measure how well Nu Skin manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.11 in 2025. Return On Capital Employed is likely to gain to -0.12 in 2025. At this time, Nu Skin's Total Current Assets are comparatively stable compared to the past year. Intangible Assets is likely to gain to about 83 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 621.2 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| W McFadden | Flowers Foods | 38 | |
| James Spear | Flowers Foods | 65 | |
| Jesse Lynn | Herbalife Nutrition | 49 | |
| Bernd Kessler | Polaris Industries | 62 | |
| Richard Carmona | Herbalife Nutrition | 71 | |
| Margaret Lewis | Flowers Foods | 66 | |
| Lawrence Kingsley | Polaris Industries | 58 | |
| Gilbert Fuller | USANA Health Sciences | 80 | |
| John Tartol | Herbalife Nutrition | 69 | |
| Gwenne Henricks | Polaris Industries | 63 | |
| Feng Peng | USANA Health Sciences | 46 | |
| Benjamin Griswold | Flowers Foods | 79 | |
| Sophie LHelias | Herbalife Nutrition | 57 | |
| Kevin Jones | Herbalife Nutrition | 52 | |
| Robert Anciaux | USANA Health Sciences | 74 | |
| Margarita PalauHernandez | Herbalife Nutrition | 63 | |
| Juan Mendoza | Herbalife Nutrition | 47 | |
| Annette Clayton | Polaris Industries | 56 | |
| Michael Montelongo | Herbalife Nutrition | 63 | |
| Alan LeFevre | Herbalife Nutrition | 61 | |
| James Nelson | Herbalife Nutrition | 69 | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | 0.0342 |
Nu Skin Enterprises Leadership Team
Elected by the shareholders, the Nu Skin's board of directors comprises two types of representatives: Nu Skin inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NUS. The board's role is to monitor Nu Skin's management team and ensure that shareholders' interests are well served. Nu Skin's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nu Skin's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Pond, Director - Investor Relations | ||
| Ritch Wood, CFO, Principal Accounting Officer and VP | ||
| Chayce Clark, Executive Vice President General Counsel | ||
| Joseph Chang, Executive Vice President - Product Development, Chief Scientific Officer | ||
| Ruth Todd, Senior Officer | ||
| Emma Battle, Director | ||
| Thomas Pisano, Independent Director | ||
| Mark Adams, Chief Officer | ||
| Zheqing Shen, Independent Director | ||
| James Thomas, Chief Accounting Officer | ||
| Mang Tang, Strategic Advisor | ||
| Joe Sueper, Senior CTO | ||
| Steven Hatchett, Executive Officer | ||
| Mark Lawrence, Chief Financial Officer, Executive Vice President | ||
| Sandra Tillotson, Founder | ||
| D Dorny, Executive Vice President, General Counsel, Secretary | ||
| Steve Hatchett, Executive Officer | ||
| Daniel Campbell, Lead Independent Director | ||
| Edwina Woodbury, Independent Director | ||
| Laura Nathanson, Independent Director | ||
| Steven Lund, Executive Chairman of the Board | ||
| Matthew Dorny, VP, General Counsel and Secretary | ||
| Connie Tang, Executive Vice President Chief Global Growth & customer Experience Officer | ||
| Justin Keisel, President Americas | ||
| Blake Roney, Founder | ||
| Steven JD, CoFounder Board | ||
| Andrew Lipman, Independent Director | ||
| Greg Belliston, Assistant Secretary | ||
| Ashok Pahwa, Chief Officer | ||
| Ryan Napierski, President, Chief Executive Officer, Director |
NUS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nu Skin a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | 0.0342 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 685.97 M | ||||
| Shares Outstanding | 49.72 M | ||||
| Shares Owned By Insiders | 3.41 % | ||||
| Shares Owned By Institutions | 77.58 % | ||||
| Number Of Shares Shorted | 2.19 M | ||||
| Price To Earning | 10.70 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NUS Stock Analysis
When running Nu Skin's price analysis, check to measure Nu Skin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu Skin is operating at the current time. Most of Nu Skin's value examination focuses on studying past and present price action to predict the probability of Nu Skin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nu Skin's price. Additionally, you may evaluate how the addition of Nu Skin to your portfolios can decrease your overall portfolio volatility.